Alexandria Real Estate Equities, Inc. reports news as a life science real estate investment trust that owns, operates and develops collaborative Megacampus™ ecosystems in major life science innovation clusters. Company updates commonly cover operating results, funds from operations, leasing activity, rental-rate trends and property-market demand across locations such as Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City.
Recurring announcements also include quarterly common stock dividends, balance-sheet and liquidity commentary, capital recycling activity, senior note offerings, cash tender offers for outstanding debt and corporate governance or leadership matters tied to the REIT’s public-company structure.
Alexandria Real Estate Equities (NYSE: ARE) declared a quarterly cash dividend of $0.72 per common share for 1Q26. The dividend is payable on April 15, 2026 to holders of record on March 31, 2026.
The payment matches the prior quarter, yields 5.2% based on the February 26, 2026 close, and reflects a quarterly dividend payout ratio of 33% of quarterly funds from operations for the three months ended December 31, 2025.
Alexandria Real Estate Equities (NYSE: ARE) will hold a conference call and live audio webcast on April 28, 2026 at 2:00 p.m. ET to discuss first quarter 2026 operating and financial results. The company will release results after market close on April 27, 2026.
Dial-in numbers are provided for U.S./Canada and international participants, and a replay will be available from 4:00 p.m. ET on April 28 through 4:00 p.m. ET on May 5, 2026 with an access code.
Alexandria Real Estate Equities (NYSE: ARE) priced a public offering of $750,000,000 aggregate principal amount of 5.25% senior notes due 2036 at 99.679% with a yield to maturity of 5.291%. The notes are unsecured and fully guaranteed by an indirectly 100% owned subsidiary.
Closing is expected on or about February 25, 2026. Net proceeds are expected to repay commercial paper used in connection with repurchase or redemption of certain outstanding notes aggregating $952,202,784.40, with any remaining proceeds used for short-term investments or general corporate purposes.
Alexandria Real Estate Equities (NYSE: ARE) announced pricing and terms for cash tender offers to purchase up to an Aggregate Maximum Tender Amount of $952,202,784.40 of its 2050, 2051 and 2052 senior notes.
Key terms: Early Tender Date Feb 9, 2026; Early Settlement Date expected Feb 12, 2026; Early Tender Premium $50 per $1,000; Total Consideration per $1,000: $656.22 (2051), $726.53 (2052), $790.86 (2050). Acceptance priority levels and financing conditions apply.
Alexandria Real Estate Equities (NYSE: ARE) announced an underwritten public offering of senior notes on Feb 10, 2026. The notes will be unsecured obligations of the company and fully guaranteed by an indirectly 100% owned subsidiary. Net proceeds are expected to repay commercial paper used in a prior cash tender offer; pending use proceeds may be invested in short-term securities or used for general corporate purposes.
Alexandria Real Estate Equities (NYSE: ARE) reported early results of cash tender offers for its 2050, 2051 and 2052 senior notes and has increased the Aggregate Maximum Tender Amount to accept all Notes validly tendered and not withdrawn as of the Early Tender Date (Feb 9, 2026).
As of 5:00 p.m. ET on Feb 9, 2026, holders tendered $497.602M of 3.000% notes due 2051, $524.594M of 3.550% notes due 2052 and $309.199M of 4.000% notes due 2050. Acceptance remains subject to financing conditions.
Alexandria Real Estate Equities (NYSE: ARE) commenced cash tender offers to purchase up to an aggregate purchase price not to exceed $800,000,000 of its outstanding 2051, 2052 and 2050 senior notes.
Offers include an Early Tender Premium of $50 per $1,000, fixed spreads of +75–+80 bps over a 4.750% U.S. Treasury reference, priority acceptance levels, expected settlement in February 2026 and a $500,000,000 financing condition.
Alexandria Real Estate Equities (NYSE: ARE) reported results for the quarter and year ended December 31, 2025. Net loss per diluted share was $(6.35) for 4Q25 and $(8.44) for 2025, while FFO per diluted share, as adjusted was $2.16 for 4Q25 and $9.01 for 2025. The company ended 2025 with 90.9% operating occupancy, $5.30 billion of liquidity, and net debt plus preferred to Adjusted EBITDA of 5.7x (4Q25 annualized).
Actions included a 45% reduction in the quarterly common dividend to $0.72, $1.81 billion of dispositions in 2025, a $500 million repurchase authorization, and reiterated 2026 FFO guidance of $6.25–$6.55 per share.
Alexandria Real Estate Equities (NYSE: ARE) reported the tax composition of its 2025 distributions. Total distributions paid were $5.280000 per share (four quarterly payments of $1.32 each). The taxable ordinary dividend component (Box 1a) totaled $3.517008 per share, representing 66.61% of the total. Qualified dividend amounts totaled $0.762960 per share. Return of capital was $0.033264 per share and Section 199A dividends totaled $0.250008 per share. No Section 897 capital gains were reported. Stockholders are advised to consult their tax advisors for individual treatment.
Alexandria Real Estate Equities (NYSE: ARE) marked its 32nd anniversary on Jan 5, 2026, highlighting its role as a pioneer in life science real estate and Megacampus ecosystems that support drug development and innovation.
Key reported metrics through Sept 30, 2025: 71% of annual rental revenue came from Greater Boston, San Francisco Bay Area, and San Diego; Megacampus occupancy was 91% (+18% vs. market); combined leasing volume in those three markets equaled ~105% of the next five largest owners from Jan 1, 2023–Sept 30, 2025; and five-year average tenant retention exceeded 80%. The company also said 39% of the 44 novel therapies approved by FDA in 2025 were developed or commercialized by Alexandria tenants.
Alexandria plans a public-private partnership MAP-D clinical study targeting a May 2026 launch to identify biomarkers for depression.